Evidence map›Paper›PMID 32589646›Full record

ArticlePLoS neglected tropical diseases2020

Development of an ELISA for the quantification of mycolactone, the cytotoxic macrolide toxin of Mycobacterium ulcerans.

Louisa Warryn, Jean-Pierre Dangy, Philipp Gersbach, Matthias Gehringer, Anja Schäfer, Marie-Thérèse Ruf, Nicolas Ruggli, Karl-Heinz Altmann, Gerd Pluschke

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Buruli ulcer.Nature reviews. Disease primers · 2025
    Review
  2. Review
  3. Pilot use of a mycolactone-specific lateral flow assay for Buruli ulcer: A case report from Japan.Journal of clinical tuberculosis and other mycobacterial diseases · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Louisa WarrynSwiss Tropical and Public Health Institute, Basel, Switzerland.ORCID 0000-0001-8660-1242
Jean-Pierre DangySwiss Tropical and Public Health Institute, Basel, Switzerland.
Philipp GersbachDepartment of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zürich, Zürich, Switzerland.
Matthias GehringerDepartment of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zürich, Zürich, Switzerland.
Anja SchäferSwiss Tropical and Public Health Institute, Basel, Switzerland.
Marie-Thérèse RufSwiss Tropical and Public Health Institute, Basel, Switzerland.
Nicolas RuggliThe Institute of Virology and Immunology IVI, Mittelhäusern, Switzerland.
Karl-Heinz AltmannDepartment of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zürich, Zürich, Switzerland.
Gerd PluschkeSwiss Tropical and Public Health Institute, Basel, Switzerland.ORCID 0000-0003-1957-2925
Swiss Tropical and Public Health Institute · CHETH Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycolactones, macrolide cytotoxins, are key virulence factors of Mycobacterium ulcerans, the etiological agent of the chronic necrotizing skin disease Buruli ulcer. There is urgent need for a simple point-of-care laboratory test for Buruli ulcer and mycolactone represents a promising target for the development of an immunological assay. However, for a long time, all efforts to generate mycolactone-specific antibodies have failed. By using a protein conjugate of a truncated non-toxic synthetic mycolactone derivative, we recently described generation of a set of mycolactone-specific monoclonal antibodies. Using the first mycolactone-specific monoclonal antibodies that we have described before, we were able to develop an antigen competition assay that detects mycolactones. By the systematic selection of a capturing antibody and a reporter molecule, and the optimization of assay conditions, we developed an ELISA that detects common natural variants of mycolactone with a limit of detection in the low nanomolar range. The mycolactone-specific ELISA described here will be a very useful tool for research on the biology of this macrolide toxin. After conversion into a simple point-of-care test format, the competition assay may have great potential as laboratory assay for both the diagnosis of Buruli ulcer and for the monitoring of treatment efficacy.

Indexed as

AnimalsAntibodies, MonoclonalBuruli UlcerDisease Models, AnimalEnzyme-Linked Immunosorbent AssayHumansMacrolidesMiceMice, Inbred BALB CMolecular Diagnostic TechniquesMycobacterium ulceransSensitivity and SpecificityAntibodies, MonoclonalMacrolidesmycolactone

Identifiers

PMID32589646
PMCPMC7347236
OpenAlexW3037909599

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.